Transdermal Scopolamine in the Treatment of Vertiginous Episodes Associated with Ménière’s Disease
The parasympatholytic drugs, the antihistamines, and the phenothiazine tranquilizers all have a central depressant action and have long been used in preventing or treating motion sickness. The most widely used drugs are those with few atropine-like or sedative side-effects and thanks to the interest of the armed forces, many field studies and clinical trials evaluating drugs against motion sickness are available [1, 2]. In 1966, Brand and Perry  compiled exhaustive reviews on drugs used in motion sickness. They reported that there is no substitute for l-hyoscine (scopolamine) where the aim is to provide quick action but short-term protection against exposure to severe motion, but that for the prophylaxis of motion sickness during a long voyage, the diphenhydramine, cyclizine, may afford adequate protection.
KeywordsMotion Sickness Vestibular Nucleus Remission Group Aviat Space Environ Scopolamine Hydro Bromide
Unable to display preview. Download preview PDF.
- 4.Shaw JE, Bayne W, Schmitt LG (1976) Clinical pharmacology of scopolamine. Clin Pharmacol Ther 19: 15–19Google Scholar
- 5.Wood CD, Graybiel A (1970) Evaluation of antimotion sickness drugs. A new effective remedy revealed. Aerospace Med 41: 932–933Google Scholar
- 7.Shute CC, Lewis PR (1965) Cholinesterase-containing pathways of the hindbrain. Afferent cerebellar and centrifugal cochlear fibers. Nature 205: 242–246Google Scholar
- 9.Balon RW (1983) The dizzy patient. Symptomatic treatment of vertigo. Postgrad Med 73: 317–324Google Scholar
- 12.Lenore G, Schmitt RN, Shaw JE (1986) Alleviation of induced vertigo. Arch Otolaryngol Head Neck Surg 112: 88–91Google Scholar